CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Formulate up-to-date management strategies for patients with small cell lung cancer (SCLC), considering the roles of local therapy, chemotherapy and immunotherapy.
  • Review long-term data supporting the use of atezolizumab or durvalumab in combination with platinum-based chemotherapy as first-line therapy for patients with extensive-stage SCLC, and consider how these regimens can be appropriately and safely integrated into clinical practice.
  • Consider the FDA approval of and available clinical trial findings with lurbinectedin for patients with SCLC who experience disease progression on or after platinum-containing therapy, and determine how to integrate this agent optimally into treatment algorithms.
  • Compare and contrast the side effects associated with recently approved agents and strategies in the treatment of SCLC, and formulate supportive management strategies to minimize and manage these toxicities.
  • Recall the mechanism of action and recent FDA approval of the novel reversible CDK4/6 inhibitor trilaciclib, and consider the use of this agent to reduce chemotherapy-induced bone marrow suppression in patients with extensive-stage SCLC.
  • Assess ongoing clinical research evaluating novel agents and treatment strategies under development for the management of SCLC, and counsel patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Luis Paz-Ares, MD, PhD
  Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
  Associate Professor at the Universidad Complutense
  Head of the Lung Cancer Unit at the National Oncology Research Center
  Madrid, Spain
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi Genzyme, Takeda Pharmaceutical Company Limited; Board of Directors: Altum Sequencing, GENOMICA; Contracted Research: Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, IO Biotech, Janssen Biotech Inc, Lilly, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi Genzyme, Takeda Pharmaceutical Company Limited, Tesaro, A GSK Company.
  
  Jared Weiss, MD
  Professor of Medicine
  UNC School of Medicine
  Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Azitra, Boehringer Ingelheim Pharmaceuticals Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Jazz Pharmaceuticals Inc, Lilly, Nanobiotix, Pfizer Inc, Regeneron Pharmaceuticals Inc, Saatchi & Saatchi Wellness, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics Inc, Inspirna, Merck; Data and Safety Monitoring Board/Committee: BeiGene Ltd, EMD Serono Inc, Jounce Therapeutics; Ownership Interest: Achilles Therapeutics, Lyell, Nuvalent, Vesselon (warrants).
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, G1 Therapeutics Inc and Jazz Pharmaceuticals Inc.
  
  Release date: February 2022
  Expiration date: February 2023